Original Drug Products. Vertex shall pay to CFFT the following royalties on aggregate Net Sales of [***] Drug Product, First [***]) and Second Generation Corrector Drug Products (together, the “Original Drug Products”) in the Field: (i) [***] Net Sales of Original Drug Products in the Field that are [***]; (ii) [***] Net Sales of Original Drug Products in the Field [***]. The foregoing rates shall be effective as of [***]. All royalties payable on the Original Drug Products for the period from [***] through [***] shall be payable in accordance with the methodology for calculating royalties on Original Drug Products contained in the royalty reports delivered by Vertex to CFFT for the first and second calendar quarters of 2016.
Appears in 3 contracts
Samples: Research, Development and Commercialization Agreement (Royalty Pharma PLC), Research, Development and Commercialization Agreement (Royalty Pharma PLC), Research, Development and Commercialization Agreement (Royalty Pharma PLC)
Original Drug Products. Vertex shall pay to CFFT the following royalties on aggregate Net Sales of [***] Drug Product, First [***]) and Second Generation Corrector Drug Products (together, the “Original Drug Products”) in the Field:
(i) i. [***] ]Net Sales of Original Drug Products in the Field that are [***];
(ii) . [***] ]Net Sales of Original Drug Products in the Field [***]. The foregoing rates shall be effective as of [***]. All royalties payable on the Original Drug Products for the period from [***] through [***] shall be payable in accordance with the methodology for calculating royalties on Original Drug Products contained in the royalty reports delivered by Vertex to CFFT for the first and second calendar quarters of 2016.
Appears in 1 contract
Samples: Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)
Original Drug Products. Vertex shall pay to CFFT the following royalties on aggregate Net Sales of [***] Drug Product, First [***]) and Second Generation Corrector Drug Products (together, the “Original Drug Products”) in the Field:
(i) [***] ]Net Sales of Original Drug Products in the Field that are [***];
(ii) [***] ]Net Sales of Original Drug Products in the Field [***]. The foregoing rates shall be effective as of [***]. All royalties payable on the Original Drug Products for the period from [***] through [***] shall be payable in accordance with the methodology for calculating royalties on Original Drug Products contained in the royalty reports delivered by Vertex to CFFT for the first and second calendar quarters of 2016.
Appears in 1 contract
Samples: Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)
